Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. INGN
INGN logo

INGN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Inogen Inc (INGN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
6.190
1 Day change
-4.77%
52 Week Range
9.130
Analysis Updated At
2026/03/27
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Inogen Inc (INGN) is not a strong buy at the moment for a beginner investor with a long-term focus. While the stock shows some potential for short-term gains, the lack of significant positive catalysts, weak financial performance, and no strong trading signals suggest it is better to hold off on investing right now.

Technical Analysis

The MACD is positive and expanding, indicating a bullish trend. RSI is neutral at 67.732, and moving averages are converging, showing no clear direction. The stock is trading near its resistance level (R1: 6.554).

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
9
Buy
3

Positive Catalysts

  • The MACD suggests a bullish trend, and the stock has a 70% chance to gain 6.11% in the next month based on historical patterns.

Neutral/Negative Catalysts

  • No recent news or significant insider/hedge fund activity. Financial performance is weak, with declining net income, EPS, and gross margin. Congress trading data is unavailable, and there are no strong trading signals from AI Stock Picker or SwingMax.

Financial Performance

In 2025/Q4, revenue increased by 2.05% YoY to $81.72M. However, net income dropped by -26.96% YoY to -$7.13M, EPS fell by -36.59% YoY to -0.26, and gross margin declined by -4.85% YoY to 43.12%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target changes are available for INGN.

Wall Street analysts forecast INGN stock price to rise
2 Analyst Rating
Wall Street analysts forecast INGN stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.190
sliders
Low
12
Averages
13
High
14
Current: 6.190
sliders
Low
12
Averages
13
High
14
B. Riley
NULL -> Buy
initiated
$14
AI Analysis
2025-06-17
Reason
B. Riley
Price Target
$14
AI Analysis
2025-06-17
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Inogen with a Buy rating and $14 price target.
B. Riley
Anderson Schock
Buy
initiated
$14
2025-06-17
Reason
B. Riley
Anderson Schock
Price Target
$14
2025-06-17
initiated
Buy
Reason
B. Riley analyst Anderson Schock last night initiated coverage of Inogen with a Buy rating and $14 price target. Inogen is a global leader in portable oxygen therapy, targeting chronic obstructive pulmonary disease patients, the analyst tells investors in a research note. The firm says the company's portable oxygen concentrators convert ambient air into medical-grade oxygen, allowing for greater patient mobility than traditional oxygen tanks. It believes Inogen represents a "compelling turnaround story" following a management transition in Q4 of 2023 focused on reducing friction among sales channels and on cost management strategies to drive sustainable and profitable growth. Riley views Inogen "deeply undervalued" and is encouraged by the company's turnaround momentum and five consecutive quarters of beating the Street's estimates.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for INGN
Unlock Now

People Also Watch